← Leaderboards
Joseph Stone Doggett
Portland Va Medical Center
$229,542
Attributed
$688,626
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $688.6K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$688,626 · 1
VA$0 · 3
By mechanism
R01$688,626 · 1
I01$0 · 2
IK2$0 · 1
Top collaborators
- Choukri Ben Mamoun1 shared
- Michael Kevin Riscoe1 shared
Most similar at Portland Va Medical Center
Same institution · by research overlap
- Michael Kevin Riscoe$14,982,665
- Jonathan E Elliott$0
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionIn VitroOralPharmaceutical PreparationsLeadVeteransPreclinical TestingProdrugsBiological AvailabilityQuinolonesAtovaquoneIn VivoSiteBaseDrug KineticsDrug ResistanceAcuteCaringDrug DiscoveryPlasmodiumToxoplasma GondiiToxoplasmosisMalariaEnzymes
Grant awards (14)
Novel Therapeutic Strategies for ELQ-422, a preclinical Toxoplasmosis Drug Candidate$0
I01 · FY2025 · VA · contact PI
Novel Therapeutic Strategies for ELQ-422, a preclinical Toxoplasmosis Drug Candidate$0
I01 · FY2024 · VA · contact PI
Advanced Preclinical Testing of a Broad-Spectrum Antiparasitic Quinolones for Veteran Health$0
I01 · FY2022 · VA · contact PI
COVID19: Optimized Endosome-Targeting Compounds for SARS-CoV-2 and Emerging Coronaviruses$0
I01 · FY2022 · VA · contact PI
COVID19: Optimized Endosome-Targeting Compounds for SARS-CoV-2 and Emerging Coronaviruses$0
I01 · FY2021 · VA · contact PI
Advanced Preclinical Testing of a Broad-Spectrum Antiparasitic Quinolones for Veteran Health$0
I01 · FY2021 · VA · contact PI
Advanced Preclinical Testing of a Broad-Spectrum Antiparasitic Quinolones for Veteran Health$0
I01 · FY2020 · VA · contact PI
Advanced Preclinical Testing of a Broad-Spectrum Antiparasitic Quinolones for Veteran Health$0
I01 · FY2019 · VA · contact PI
Development of the potent anti-malarial and anti-Toxoplasma drug, ELQ-316$0
IK2 · FY2018 · VA · contact PI
Development of endochin-like quinolones for babesiosis therapy$688,626
R01 · FY2017 · AI
Development of the potent anti-malarial and anti-Toxoplasma drug, ELQ-316$0
IK2 · FY2017 · VA · contact PI
Development of the potent anti-malarial and anti-Toxoplasma drug, ELQ-316$0
IK2 · FY2016 · VA · contact PI
Development of the potent anti-malarial and anti-Toxoplasma drug, ELQ-316$0
IK2 · FY2015 · VA · contact PI
Development of the potent anti-malarial and anti-Toxoplasma drug, ELQ-316$0
IK2 · FY2014 · VA · contact PI